Shenzhen, September 29, 2022 -- Ailurus Biotechnology Co., Ltd., the biocomputer company, announced that the first synthetic organelle in bacteria, "TEARS", was published in the journal Cell [1], and that Ailurus provided a development kit TEAR-2 to its customers for engineering phase separations.

Organelles are specialized subunits that perform various work in cells. It's been taught in textbooks for decades that organelle is a featured structure of eukaryotic kingdoms and doesn't exist in bacteria. Yet a research group built synthetic organelles in bacteria, and overturned this orthodox, co-led by Haotian Guo, cofounder and CEO of Ailurus.

Dr. Guo conceived a design to build synthetic organelles in Escherichia coli by engineering RNAs that can phase separate without extra aids. Phase separation is a process similar to water-oil demixing, commonly observed to form membraneless organelles, namely biocondensates, in eukaryotes. In 2017 iGEM competition, Dr. Guo instructed team Paris Bettencourt presented its prototype "RNA organelle". Dr. Guo recalled, "It was a bold move, as no evidence showed that phase separation was even physically possible in bacteria at the time." This work remarks the first public record of biocondensate in bacteria, even earlier than the discovery of natural ones by Al-Husini et al 2018. Then, Dr. Guo and Professor Ariel B. Lindner from French national biomedical research institute (INSERM) at Université de Paris Cité led a group to further develop it into a comprehensive study, "TEARS". Until now, TEARS has been the only synthetic complexes whose structures and functionalities are reminiscent of its eukaryotic counterparts.